180 related articles for article (PubMed ID: 31270105)
1. Increased SLAMF7
Maekawa T; Kato S; Kawamura T; Takada K; Sone T; Ogata H; Saito K; Izumi T; Nagao S; Takano K; Okada Y; Tachi N; Teramoto M; Horiuchi T; Hikota-Saga R; Endo-Umeda K; Uno S; Osawa Y; Kobayashi A; Kobayashi S; Sato K; Hashimoto M; Suzu S; Usuki K; Morishita S; Araki M; Makishima M; Komatsu N; Kimura F
Blood; 2019 Sep; 134(10):814-825. PubMed ID: 31270105
[TBL] [Abstract][Full Text] [Related]
2. [The role of fibrocytes in myelofibrosis and fibrocyte regulation as a novel treatment approach].
Maekawa T; Kato S; Kimura F
Rinsho Ketsueki; 2020; 61(1):3-10. PubMed ID: 32023599
[TBL] [Abstract][Full Text] [Related]
3. Neoplastic fibrocytes play an essential role in bone marrow fibrosis in Jak2V617F-induced primary myelofibrosis mice.
Ozono Y; Shide K; Kameda T; Kamiunten A; Tahira Y; Sekine M; Akizuki K; Nakamura K; Iwakiri H; Sueta M; Hidaka T; Kubuki Y; Yamamoto S; Hasuike S; Sawaguchi A; Nagata K; Shimoda K
Leukemia; 2021 Feb; 35(2):454-467. PubMed ID: 32472085
[TBL] [Abstract][Full Text] [Related]
4. The JAK2V617F tyrosine kinase mutation has no impact on overall survival and the risk of leukemic transformation in myelofibrosis.
Helbig G; Wieczorkiewicz A; Woźniczka K; Wiśniewska-Piąty K; Rusek A; Kyrcz-Krzemień S
Med Oncol; 2012 Dec; 29(4):2379-84. PubMed ID: 22383244
[TBL] [Abstract][Full Text] [Related]
5. Enhanced SLAMF7 Homotypic Interactions by Elotuzumab Improves NK Cell Killing of Multiple Myeloma.
Pazina T; James AM; Colby KB; Yang Y; Gale A; Jhatakia A; Kearney AY; Graziano RF; Bezman NA; Robbins MD; Cohen AD; Campbell KS
Cancer Immunol Res; 2019 Oct; 7(10):1633-1646. PubMed ID: 31431433
[TBL] [Abstract][Full Text] [Related]
6. Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele.
Guglielmelli P; Barosi G; Specchia G; Rambaldi A; Lo Coco F; Antonioli E; Pieri L; Pancrazzi A; Ponziani V; Delaini F; Longo G; Ammatuna E; Liso V; Bosi A; Barbui T; Vannucchi AM
Blood; 2009 Aug; 114(8):1477-83. PubMed ID: 19549988
[TBL] [Abstract][Full Text] [Related]
7. Loss of Ezh2 cooperates with Jak2V617F in the development of myelofibrosis in a mouse model of myeloproliferative neoplasm.
Yang Y; Akada H; Nath D; Hutchison RE; Mohi G
Blood; 2016 Jun; 127(26):3410-23. PubMed ID: 27081096
[TBL] [Abstract][Full Text] [Related]
8. Consequences of the JAK2V617F allele burden for the prediction of transformation into myelofibrosis from polycythemia vera and essential thrombocythemia.
Shirane S; Araki M; Morishita S; Edahiro Y; Sunami Y; Hironaka Y; Noguchi M; Koike M; Sato E; Ohsaka A; Komatsu N
Int J Hematol; 2015 Feb; 101(2):148-53. PubMed ID: 25522845
[TBL] [Abstract][Full Text] [Related]
9. Thromboses and hemorrhages are common in MPN patients with high JAK2V617F allele burden.
Bertozzi I; Bogoni G; Biagetti G; Duner E; Lombardi AM; Fabris F; Randi ML
Ann Hematol; 2017 Aug; 96(8):1297-1302. PubMed ID: 28585070
[TBL] [Abstract][Full Text] [Related]
10. JAK2V617F molecular remission in a primary myelofibrosis patient treated with ruxolitinib.
Koehler A; Hubert K; Lange T; Siebolts U; Wickenhauser C; Gopalakrishna P; Niederwieser D; Monecke A; Al-Ali HK
Ann Hematol; 2015 Nov; 94(11):1929-30. PubMed ID: 26202608
[No Abstract] [Full Text] [Related]
11. Myeloproliferative leukemia protein activation directly induces fibrocyte differentiation to cause myelofibrosis.
Maekawa T; Osawa Y; Izumi T; Nagao S; Takano K; Okada Y; Tachi N; Teramoto M; Kawamura T; Horiuchi T; Saga R; Kato S; Yamamura T; Watanabe J; Kobayashi A; Kobayashi S; Sato K; Hashimoto M; Suzu S; Kimura F
Leukemia; 2017 Dec; 31(12):2709-2716. PubMed ID: 28386106
[TBL] [Abstract][Full Text] [Related]
12. Elotuzumab, a potential therapeutic humanized anti-SLAMF7 monoclonal antibody, enhances natural killer cell-mediated killing of primary effusion lymphoma cells.
Panaampon J; Kariya R; Okada S
Cancer Immunol Immunother; 2022 Oct; 71(10):2497-2509. PubMed ID: 35262781
[TBL] [Abstract][Full Text] [Related]
13. Correlative study between the JAK2V617F mutation and thrombosis in patients with myeloproliferative neoplasm.
Li ZC; Fu HJ; Wang ZM; Yang S; Xu HZ
Genet Mol Res; 2016 Aug; 15(3):. PubMed ID: 27706633
[TBL] [Abstract][Full Text] [Related]
14. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
Pikman Y; Lee BH; Mercher T; McDowell E; Ebert BL; Gozo M; Cuker A; Wernig G; Moore S; Galinsky I; DeAngelo DJ; Clark JJ; Lee SJ; Golub TR; Wadleigh M; Gilliland DG; Levine RL
PLoS Med; 2006 Jul; 3(7):e270. PubMed ID: 16834459
[TBL] [Abstract][Full Text] [Related]
15. [JAK2V617F mutation and TNF-α expression in myeloproliferative neoplasms and their correlation].
Sun CC; Li Y; Tian WJ; Chen YJ; Zhang LY; Liu X; Shan NN
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug; 22(4):1022-6. PubMed ID: 25130821
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma.
Campbell KS; Cohen AD; Pazina T
Front Immunol; 2018; 9():2551. PubMed ID: 30455698
[TBL] [Abstract][Full Text] [Related]
17. Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot study.
Chang H; Shih LY; Michelson AD; Dunn P; Frelinger AL; Wang PN; Kuo MC; Lin TL; Wu JH; Tang TC
Acta Haematol; 2013; 130(3):181-7. PubMed ID: 23751441
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-1 contributes to clonal expansion and progression of bone marrow fibrosis in JAK2V617F-induced myeloproliferative neoplasm.
Rahman MF; Yang Y; Le BT; Dutta A; Posyniak J; Faughnan P; Sayem MA; Aguilera NS; Mohi G
Nat Commun; 2022 Sep; 13(1):5347. PubMed ID: 36100596
[TBL] [Abstract][Full Text] [Related]
19. Concomitant and noncanonical JAK2 and MPL mutations in JAK2V617F- and MPLW515 L-positive myelofibrosis.
Schulze S; Stengel R; Jaekel N; Wang SY; Franke GN; Roskos M; Schneider M; Niederwieser D; Al-Ali HK
Genes Chromosomes Cancer; 2019 Nov; 58(11):747-755. PubMed ID: 31135094
[TBL] [Abstract][Full Text] [Related]
20. Genetic ablation of Pim1 or pharmacologic inhibition with TP-3654 ameliorates myelofibrosis in murine models.
Dutta A; Nath D; Yang Y; Le BT; Rahman MF; Faughnan P; Wang Z; Stuver M; He R; Tan W; Hutchison RE; Foulks JM; Warner SL; Zang C; Mohi G
Leukemia; 2022 Mar; 36(3):746-759. PubMed ID: 34741118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
